<DOC>
	<DOCNO>NCT00891839</DOCNO>
	<brief_summary>The purpose study determine efficacy safety combination bendamustine rituximab patient relapsed/refractory mantle cell lymphoma .</brief_summary>
	<brief_title>Bendamustine Hydrochloride Combination With Rituximab Patients With Relapsed Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>histopathologically confirm diagnosis typical atypical mantle cell lymphoma , except blastoid type . documented relapsed/refractory mantle cell lymphoma . CD20 positive B cell lymph node biopsy lymphoma pathology specimen . adequate hematologic function accord specific trial parameter . bidimensionally measurable disease least 1 lesion measure 2.0 cm single dimension , patient leukemic phase disease . patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2. patient estimate life expectancy least 3 month . woman childbearing potential ( surgically sterile 2 year postmenopausal ) must use medically accept method contraception must agree continue use method duration study 30 day participation study . men surgically sterile capable produce offspring must practice abstinence use barrier method birth control , must agree continue use method duration study drug treatment 30 day participation treatment period . receive 3 previous standard chemotherapy regimen . blastoid subtype mantle cell lymphoma . documented history central nervous system ( CNS ) lymphomatous involvement . history previous highdose chemotherapy allogeneic stem cell transplantation ( history autologous stem cell transplantation allow ) . previous treatment bendamustine . active malignancy MCL , malignancy MCL within past 3 year , except control prostate cancer without evidence bone metastasis , localize bladder cancer , cervical carcinoma situ , breast cancer situ , nonmelanoma skin cancer . New York Heart Association ( NYHA ) Class III IV heart failure , arrhythmia unstable angina , electrocardiographic evidence active ischemia active conduction system abnormality , myocardial infarction within last 6 month . serum creatinine 2.0 mg/dL creatinine clearance le 30 mL/min base CockcroftGault method 24hour urine collection . adequate hepatic organ function evidence specific trial parameter . know human immunodeficiency virus ( HIV ) infection . active hepatitis B infection . Hepatitis B surface antigen must test . pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) receive corticosteroid within 28 day study entry unless chronically administer ( prednisone â‰¤20 mg/day ) indication lymphoma lymphomarelated complication . serious uncontrolled , medical psychological disorder would impair ability patient participate complete study . condition place patient unacceptable risk confounds ability investigator interpret study data . patient receive investigational agent ( ) within 28 day study entry . patient receive chemotherapy within prior 28 day . patient know hypersensitivity bendamustine , mannitol , rituximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>